1. Home
  2. BGLC vs INAB Comparison

BGLC vs INAB Comparison

Compare BGLC & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$3.95

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$2.49

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGLC
INAB
Founded
2017
2016
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
10.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BGLC
INAB
Price
$3.95
$2.49
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$108.00
AVG Volume (30 Days)
22.6K
698.3K
Earning Date
11-14-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,465,006.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.21
N/A
52 Week Low
$2.01
$1.17
52 Week High
$15.60
$12.53

Technical Indicators

Market Signals
Indicator
BGLC
INAB
Relative Strength Index (RSI) 33.82 68.28
Support Level $3.98 $1.17
Resistance Level $4.04 $2.24
Average True Range (ATR) 0.13 0.26
MACD 0.01 0.11
Stochastic Oscillator 14.97 92.96

Price Performance

Historical Comparison
BGLC
INAB

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: